Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

17.80 -0.12 (-0.70%)
Streaming Delayed Price Updated: 2:22 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,025,372
Open 18.16
Bid (Size) 17.76 (3)
Ask (Size) 17.83 (4)
Prev. Close 17.92
Today's Range 17.75 - 18.90
52wk Range 5.120 - 25.29
Shares Outstanding 60,717,176
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
From Travere Therapeutics, Inc.
Via Business Wire

Performance

YTD
-6.2%
-6.2%
1 Month
-10.1%
-10.1%
3 Month
+2.7%
+2.7%
6 Month
+27.2%
+27.2%
1 Year
+143.4%
+143.4%

More News

Read More
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
From Travere Therapeutics, Inc.
Via GlobeNewswire
Analyst Expectations For Travere Therapeutics's Future
Via Benzinga
Earnings Scheduled For February 20, 2025
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Sparks Retail Frenzy As Stock Hits Over 2-Year High On FDA Approval Plan For Kidney-Disease Drug
Via Stocktwits
Exposures Product Safety
Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug
Via Investor's Business Daily
Exposures Product Safety
Lattice Semiconductor, SelectQuote, Radiant Logistics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Provides Corporate Update and 2025 Outlook
From Travere Therapeutics, Inc.
Via GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
From Travere Therapeutics, Inc.
Via GlobeNewswire
3 Under-the-Radar Healthcare Companies
Via MarketBeat
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Proposed Public Offering of Common Stock
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Third Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Travere Therapeutics, Inc. - Common Stock publicly traded?
Yes, Travere Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Travere Therapeutics, Inc. - Common Stock trade on?
Travere Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Travere Therapeutics, Inc. - Common Stock?
The ticker symbol for Travere Therapeutics, Inc. - Common Stock is TVTX on the Nasdaq Stock Market
What is the current price of Travere Therapeutics, Inc. - Common Stock?
The current price of Travere Therapeutics, Inc. - Common Stock is 17.80
When was Travere Therapeutics, Inc. - Common Stock last traded?
The last trade of Travere Therapeutics, Inc. - Common Stock was at 04/01/25 02:22 PM ET
What is the market capitalization of Travere Therapeutics, Inc. - Common Stock?
The market capitalization of Travere Therapeutics, Inc. - Common Stock is 1.08B
How many shares of Travere Therapeutics, Inc. - Common Stock are outstanding?
Travere Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.